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miR-23b/SP1/c-myc forms a feed-forward loop supporting
multiple myeloma cell growth
M Fulciniti1,6, N Amodio2,6, RL Bandi1, A Cagnetta1, MK Samur1, C Acharya1, R Prabhala1,3, P D’Aquila4, D Bellizzi4, G Passarino4,
S Adamia1, A Neri5, ZR Hunter1, SP Treon1, KC Anderson1, P Tassone2 and NC Munshi1,3
Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here a novel
c-Myc/miR-23b/Sp1 feed-forward loop with a critical role in multiple myeloma (MM) and Waldenstrom’s macroglobulinemia
(WM) cell growth and survival. We have found miR-23b to be downregulated in MM and WM cells especially in the presence of
components of the tumor bone marrow milieu. Promoter methylation is one mechanism of miR-23b suppression in myeloma.
In gain-of-function studies using miR-23b mimics-transfected or in miR-23b-stably expressing MM and WM cell lines, we observed
a signiﬁcant decrease in cell proliferation and survival, along with induction of caspase-3/7 activity over time, thus supporting
a tumor suppressor role for miR-23b. At the molecular level, miR-23b targeted Sp1 3′UTR and signiﬁcantly reduced Sp1-driven
nuclear factor-κB activity. Finally, c-Myc, an important oncogenic transcription factor known to stimulate MM cell proliferation,
transcriptionally repressed miR-23b. Thus MYC-dependent miR-23b repression in myeloma cells may promote activation
of oncogenic Sp1-mediated signaling, representing the ﬁrst feed-forward loop with critical growth and survival role in myeloma.
Blood Cancer Journal (2016) 6, e380; doi:10.1038/bcj.2015.106; published online 15 January 2016
INTRODUCTION
The majority of oncogenic signaling pathways converge on sets
of transcription factors (TFs) that ultimately control gene
expression patterns involved in tumor formation and
progression.1 Consequently, TF genes have been linked to cancer
pathogenesis and drug resistance, making them attractive targets
for therapy.2 In multiple myeloma (MM), a wide deregulation of
the transcriptional machinery leading to alteration in cell cycle
pathways has been recently described by our group in clinically
annotated patient subgroups.3 Moreover, we have demonstrated
increased activity of the TF Sp1, a ubiquitous zinc-ﬁnger TF that
binds guanine–cytosine-rich elements in the promoter region of
inducible genes,4,5 in MM7,6 and Waldeström’s macroglobulinemia
(WM).8 In these malignancies, Sp1 was found to trigger the nuclear
factor-κB (NF-kB) pathway, which sustains proliferation, survival
and drug resistance in tumor cells. Importantly, genetic as well as
pharmacological targeting of Sp1 was able to reduce tumor
growth both in vitro and in vivo,6,8 thus indicating that Sp1 is a
suitable target for therapeutic intervention in MM and WM.
Expression of TFs is modulated by a number of genomic and
epigenomic changes as well as various transcriptome modiﬁers.
Among such transcriptome modiﬁers there are microRNAs
(miRNAs), small non-coding RNAs (20–22 nucleotides in length)
that play an important role in regulation of gene expression,
virtually affecting all cellular processes such as differentiation,
proliferation, survival and apoptosis.9,10 Genetic disorders and
complex diseases have been found to be associated with
perturbations of the intertwined regulatory network between
TFs and miRNAs.11 Moreover, TFs and miRNAs frequently form
feed-forward loops to regulate transcription of functionally
critical genes.12
Over the last decade, a wealth of data has emerged supporting
a role for miRNAs in MM14,13 and WM pathobiology,15,16 acting as
tumor suppressor miRNAs or onco-miRNAs. In this study, we have
identiﬁed miR-23b as a negative regulator of Sp1 expression and
provided evidence of the tumor suppressor role of miR-23b, and
its downregulation as a consequence of epigenetic mechanisms,
supporting the existence of a novel feed-forward loop with a
critical growth and survival role in MM and WM.
MATERIALS AND METHODS
Cells
MM and WM cell lines were cultured in RPMI-1640 containing 10% fetal
bovine serum, 2 mmol/l L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin. They were kindly provided by sources previously described,8
ATCC (Manassas, VA, USA) or the German Collection of Microorganisms
and Cell Cultures (Braunschweig, Germany). Primary WM and MM cells
from bone marrow aspirates from among patients following informed
consent and Dana-Farber Cancer Institute IRB approval were isolated using
Ficoll-Hypaque density gradient sedimentation. Primary CD138+ MM cells
from patients were puriﬁed using positive selection with CD138-
microbeads (MiltenyiBiotec, San Diego, CA, USA). Primary WM cells were
obtained using CD19 micro-bead selection (MiltenyiBiotec). Cell purity
(more than 90%) was conﬁrmed by ﬂow cytometric analysis. Residual
CD138− bone marrow mononuclear cells were cultured for 3–6 weeks to
generate bone marrow stromal cells. Peripheral blood mononuclear cells
were obtained either by Ficoll-Hypaque density gradient sedimentation
from healthy subjects or from patients.
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 2Department of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Salvatore
Venuta Campus, Catanzaro, Italy; 3VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA; 4Department of Biology, Ecology and Earth Science (DiBEST),
University of Calabria, Arcavacata di Rende, Cosenza, Italy and 5Department of Medical Sciences, University of Milan, Hematology 1, IRCCS Policlinico Foundation, Milan, Italy.
Correspondence: Dr NC Munshi, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
E-mail: nikhil_munshi@dfci.harvard.edu
6These two authors contributed equally to this work.
Received 20 October 2015; accepted 16 November 2015
Citation: Blood Cancer Journal (2016) 6, e380; doi:10.1038/bcj.2015.106
www.nature.com/bcj
miR23b proﬁling in MM patients
miRNA expression levels were obtained by data set GSE3705317 and
GSE1749818 or by TaqMan miRNA assays (Applied Biosystems, Carlsbad,
CA, USA).
Luciferase reporter experiments
The pGL3 Luciferase plasmid containing the NF-κB-responsive elements
cloned upstream of the ﬁreﬂy luciferase reporter gene was previously
described.8 Transfections were performed by electroporation with the Neon
transfection system (Life Technologies, Grand Island, NY, USA) at the
previously reported electroporation settings,19 and renilla luciferase from
pCMV-RL was included to normalize expression of ﬁreﬂy luciferase. The 3′UTR
segment containing the target sites for miR-23b from the Sp1 gene
(nucleotides 2503–5200) and a deletion mutant lacking nucleotides from
3774 to 3781 corresponding to the predicted miR-23b target site were
cloned in pEZX-MT01 vector were purchased from Genecopoeia (Rockville,
MD, USA). In all, 2.5 μg of the ﬁreﬂy luciferase reporter and 0.5 μg of pCMV-RL
were used; for each plate, 200 nM of the synthetic miR-23b or miR-NC was
used. Fireﬂy and Renilla luciferase activities were measured consecutively
using the dual-luciferase assay kit (Promega Corporation, Madison, WI, USA)
as previously described.20 Data are expressed as luminescence from ﬁreﬂy
luciferase divided by luminescence from renilla luciferase.
Generation of stable cell lines
To generate cells stably expressing miR-23b, NCI-H929 and MWCL1 cells
were transduced with V-(mir-cnt) or V-(mir-23b) lentiparticles according to
the protocol from the manufacturer (Biosettia, San Diego, CA, USA).
Efﬁciency of overexpression was validated by real-time PCR. Total RNA was
extracted 72 h post-tranduction using mirVana miRNA Isolation Kit
(Ambion, Thermo Fisher Scientiﬁc), followed by TaqMan miRNA assays
(Applied Biosystems, Assay ID 000400). miR-23b expression was normal-
ized on RNU44 (Applied Biosystems, Assay ID 001094). The relative level of
miR-23b expression was determined by comparing with the negative
control; V-(mir-cnt).myc precision LentiORF viral particles (Thermo Scien-
tiﬁc, Lafayette, CO, USA) were used to overexpress myc in U266 MM cells.
Transient transfection of miR-23b mimics and c-myc siRNA
Synthetic pre-miRNAs were purchased from Ambion (Applied Biosystems).
Transfections were performed by electroporation with Neon transfection
system (Life Technologies).19,21 RNA interference for c-myc was carried out
by using the TranSilent Human myc small interfering RNA (siRNA)
(Panomics, Inc., Redwood, CA, USA). Non-targeting scrambled negative
control siRNA (Panomics, Inc.) was used as a negative control.
Immunoblotting
Western blotting was performed according to previously described
protocols,19 to delineate expression levels of total protein (Sp1, survivin,
caspase-3, caspase-8, NF-κB, ERK) and phospho-speciﬁc isoforms of NF-κB
and ERK. Glyceraldehyde-3-phosphate dehydrogenase was used as a
loading control (Santa Cruz Biotechnology, St Louis, MO, USA).
Cell proliferation and viability assay
Cell proliferation was measured by [3H]thymidine (Perkin-Elmer, Boston,
MA, USA) incorporation assay.6 Cell viability was analyzed by Cell-Titer
Glow (CTG) (Promega, Madison, WI, USA). Study of caspase activity was
performed using Caspases 3–7, -8, -9 Glow assays (Promega).
Methylcellulose colony formation assays
V-(mir-cnt) or V-(mir-23b) cells were suspended in Iscove’s modiﬁed
Dulbecco's medium with 50% fetal bovine serum and plated on
methylcellulose-based media (HSC004; R&D Systems, Minneapolis, MN,
USA) containing 1.4% methylcellulose in Iscove’s modiﬁed Dulbecco's
medium, 25% fetal bovine serum, 2% bovine serum albumin, 2 mM L-
glutamine, 5 × 10− 5 M 2-mercaptoethanol, 20 ng/ml recombinant human
granulocyte macrophage colony-stimulating factor, 20 ng/ml recombinant
human interleukin (IL)-3 and 50 ng/ml recombinant human SCF. Each
condition was evaluated twice in triplicates. Colonies, deﬁned as
aggregates ⩾ 50 cells, were scored with an inverted microscope after
21 days incubation at 37 °C in a fully humidiﬁed atmosphere with 5% CO2.
Cloning of miR-23b promoter region
We cloned the promoter region of miR-23b (chromosome location: chr 9
94725317-94726771), described in Zhou et al.,22 into pGL3 basic vector.
The 1455-bp region containing the miR-23b promoter was PCR ampliﬁed
from human genomic DNA by using primers containing a 6 -bp cloning
adaptor with the SacI and XhoI restriction sites (Forward: 5′-GA
GCTCGCAGCTAGCAGGGTGATG-3′; Reverse: 5′-CTCGAGACAGGGAGCGAA
ACAGGGAGCGAACAGGTTA-3′). PCR was carried out in 100 μl containing
EpiTaq PCR Buffer 1X, 0.3 mM dNTPs, 0.3 μM of each primers, 2.5 mM MgCl2,
and PCR Enzyme 0.05 U (TaKaRa Bio, Clontech Laboratories, Mountain
View, CA, USA). The PCR reaction consisted of 30 cycles (94 °C for 15 s for
the denaturation step, 62 °C for 30 s for the annealing step and 72 °C for
2 min for the extension step). A denaturation step of 2 min at 94 °C
preceded the ﬁrst cycle while the last was followed by an extension step of
5 min at 72 °C. The resulting fragment was puriﬁed by DNA Clean &
Concentrator TM-5 kit (Zymo Research, Irvine, CA, USA) and digested with
SacI and XhoI enzymes (Promega) as recommended by the manufacturer.
Then, the fragment was puriﬁed by DNA Clean & Concentrator TM- 5 kit
(Zymo Research) and inserted by using T4 DNA ligase (Promega) into the
SacI–XhoI sites upstream of the ﬁreﬂy luciferase reporter gene in the
linearized pGL3-Basic vector (Promega). DNA construct was transformed
into Top10 Escherichia coli cells by electroporation according to the
standard protocols. The pGL3/miR-23b promoter plasmid was puriﬁed
using ZR Plasmid Miniprep Classic (Zymo Research) and analyzed by
automated sequencing in ABI PRISM 310 with the BigDye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems) to conﬁrm that the
sequence matched the original genomic sequences without PCR-
generated errors.
Quantitative DNA methylation analysis
Primers for quantitative DNA methylation experiments were designed by
using EpiDesigner, a specialized tool for Sequenom'sEpiTYPER technology.
A T7-promoter tag (CAGTAATACG ACTCACTATAGGGAGAAGGCT) was
added to the reverse primer and a 10-mer tag sequence (AGGAAGAGAG)
was added to the forward primer to balance the PCR primer length. Primer
sequences are reported in Supplementary Table S1.
Bisulﬁte treatment
Bisulﬁte conversion of DNA samples was performed by using EZ-96 DNA
Methylation-Gold Kit (Zymo Research), as previously described.23
PCR conditions and Sequenom EpiTYPER technology
The PCR reactions were performed in a total volume of 5 μl using 1 μl of
bisulﬁte-treated DNA, EpiTaq PCR Buffer 1 × , 0.4 μM of each primer, 0.3 mM
dNTP mixture, 2.5 mM of MgCl2, 0.005 U TaKaRa EpiTaq HS (TaKaRa Bio,
Clontech Laboratories). The thermal proﬁle used for the reaction included a
4 min heat activation of the enzyme at 95 °C, followed by 40 cycles of
denaturation at 94 °C for 20 s, annealing (for temperature see
Supplementary Table S1) for 30 s, extension at 72 °C for 1 min, then 1
cycle at 72 °C for 3 min. In all, 0.5 μl of each PCR product was
electrophoresed on 1.5% agarose gel to conﬁrm successful PCR ampliﬁca-
tion and ampliﬁcation speciﬁcity. Unincorporated dNTPs in the ampliﬁca-
tion products were dephosphorylated by adding 1.7 μl DNase-free water
and 0.3 μl (0.5 U) shrimp alkaline phosphatase (Sequenom, Inc., San Diego,
CA, USA). Each reaction was incubated at 37 °C for 40 min and shrimp
alkaline phosphatase was then heat inactivated for 5 min at 85 °C.
Subsequently, samples were incubated for 3 h at 37 °C with 5 μl of
T-Cleavage reaction mix (Sequenom) containing 3.21 μl RNase-free water,
0.89 μl 5 × T7 polymerase buffer, 0.22 μl T cleavage mix, 0.22 μl 100 mM
dithiothreitol, 0.40 μl T7 RNA, and DNA polymerase and 0.06 μl RNase A, for
concurrent in vitro transcription and base-speciﬁc cleavage. The samples of
cleaved fragments were then diluted with 20 μl water. Conditioning of the
cleavage reaction was performed by adding 6 mg of clean resin. Ten
nanoliters of the resultant cleavage reactions were spotted onto silicon
matrix-preloaded chips (Spectro-CHIP; Sequenom) using a MassARRAY
nanodispenser (Sequenom), and analyzed using the MassARRAY Compact
System matrix-assisted laser desorption/ionization-time-of-ﬂight mass
spectrometer (Sequenom). The spectra’s methylation ratios were calcu-
lated using EpiTYPER software v1.0 (Sequenom). The method yields
quantitative results for each of the sequence-deﬁned analytic units,
referred to as CpG units, which contain either one individual CpG site or an
aggregate of downstream CpG sites. Triplicate independent analyses from
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sodium bisulﬁte-treated DNA sample were undertaken. The effectiveness
of the entire experimental procedure was also assayed by analyzing
CpGenome Universal Unmethylated DNA (Chemicon International, Temecula,
CA, USA) and CpGenome Universal Methylated DNA (Chemicon Interna-
tional) as control. Poor-quality and non-valuable data for the quantitative
methylation of each CpG unit measured by a matrix-assisted laser
desorption/ionization-time-of-ﬂight mass spectrometer were excluded.
In vivo study
V-(mir-cnt) or V-(mir-23b) H929 cells were injected s.c. in SCID mice. Tumor
growth was measured in two perpendicular dimensions once every 3 days
using a caliper and the following formula: V= (a2x b)/2; where a is the
width of the tumor (smaller diameter) and b is the length (larger diameter).
Statistical analysis
Data were analyzed using unpaired Student's t-tests comparing
two conditions or a one-way analysis of variance with Bonferroni or
Newman–Keuls correction for multiple comparisons using the Graphpad
software. P o0.05 was considered signiﬁcant. Statistical analyses for
methylation experiments were performed using SPSS 15.0 statistical
software (SPSS Inc., Chicago, IL, USA). The difference in the methylation
rates of each CpG units as well as in global DNA methylation analysis
between untreated and treated samples was analyzed by one-way
analysis of variance and Student's t-test, with a signiﬁcance level deﬁned
as α= 0.05. Data are presented as means, and error bars in the ﬁgures
depict standard deviation (s.d.).
RESULTS
miR-23b represses TF SP1 expression and activity
Using cancer miRNA Transcriptome PCR Array (SureFIND) we ﬁrst
identiﬁed miR-23b as one of the most signiﬁcant negative
regulator of Sp1 expression (data not shown). Moreover, in silico
search for target prediction (www.microRNA.org) indicates that
Sp1 is a bona ﬁde target of miR-23b (Figure 1a). To validate 3′UTR
targeting by miR-23b, NCI-H929, MM1s and BCMW1 cells were
co-transfected with synthetic miR-23b or scrambled mimics (NC),
together with an expression vector carrying the 3′UTR of Sp1
cloned downstream of the luciferase reporter gene. A signiﬁcantly
lower luciferase activity in cells transfected with miR-23b mimics
as compared with control was detected (Figure 1b). To conﬁrm
that this inhibitory activity was dependent on the binding of
miR-23b to the predicted sequence, NCI-H929 cells were
transfected with NC or miR-23b mimics along with the plasmid
carrying the wild-type 3′UTR of Sp1 or a deletion mutant devoid of
the miR-23b target sequence. As expected, the decrease in
luciferase activity by miR-23b in cells transfected with the wild-
type 3′UTR of Sp1 was no longer observed after deletion of the
miR-23b target site (Figure 1c). Consistently, miR-23b mimics
transfection in BCMW1 and NCI-H929 cells reduced Sp1 protein
expression as well as the levels of known Sp1 transcriptional
targets such as survivin, as assessed by immunoblotting analysis; a
decrease in phosphorylated p65 (RELA) and MAPK (ERK1/2) was
also observed after miR-23b overexpression (Figure 1d). Moreover,
Figure 1. Sp1 targeting by miR-23b in MM and WM tumor cells. (a) Identiﬁcation of a miR-23b-target sequence within Sp1 3′UTR by microRNA.
org in silico target prediction. (b) Dual-luciferase assay of NCI-H929, MM1s and BCMW1 cells co-transfected with ﬁreﬂy luciferase constructs
containing a portion of the 3′UTR of Sp1 (nts 2503–5200) and 200 nM of miR-23b or scrambled oligonucleotides (NC). The ﬁreﬂy luciferase
activity was normalized to renilla luciferase activity. The data are shown as relative luciferase activity of miR-23b-transfected cells as compared
with the control (NC) of a total of six experiments from three independent transfections. *Po0.01. (c) Dual-luciferase assay of NCI-H929 cells
co-transfected with ﬁreﬂy luciferase constructs containing the 3′UTR of Sp1 or a deletion mutant lacking the predicted miR-23b target site (3′
UTR del) and 200 nM of miR-23b or scrambled oligonucleotides (NC) as indicated. The ﬁreﬂy luciferase activity was normalized to renilla
luciferase activity. *Po0.01. (d) Immunoblot analysis of Sp1, survivin, phosphorylated ERK1/2, phosphorylated p65, p65 in NCI-H929 and
BCMW1 cells transfected with 200 nM miR-23b mimics or NC. GAPDH was used as a loading control. (e) Luciferase assay of MM1s, NCI-H929
and BCMW1 cells transfected with 200 nM of miR-23b mimics or NC and a ﬁreﬂy luciferase vector carrying the NF-κB-responsive elements.
Renilla luciferase from pCMV-RL was used for normalization. Data are expressed as the ratio of ﬁreﬂy and renilla luciferase and are the mean of
three different experiments performed in triplicate. *Po0.01. Abbreviation: GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Figure 2. Relative expression of miR-23b in MM and WM tumor cells. (a) Box plot representation of mir-23b expression using Afﬁmetrix
Platform in a cohort of 38 multiple myeloma (MM) and 18 plasma cell leukemia (PCL) patients compared with normal PCs. (b) qRT–PCR
analysis of miR-23b expression in a panel of MM cell lines (n= 15), peripheral blood mononuclear cell (n= 4) and BMSCs (n= 3) from MM
patients, CD138+ from MM patients (n= 12) and PCL patients (n= 3). (c) Expression of miR-23b in WM primary cells compared with normal
CD19+ cells. (d) MM and WM cell lines were treated either with 10 ng/ml of IL-6, 100 ng/ml IL-17 or supernatant from tumor-derived BMSC
suppressed the expression of miR-23b for 24 h. miR-23b expression was assessed by qRT–PCR using RNU44 as a loading control.
Abbreviations: BMSC, bone marrow stromal cell; qRT–PCR, quantitative reverse transcriptase–PCR.
Figure 3. miR-23b promoter is hypermethylated in MM cells. Sequenom’s EpiTYPER epigram panel representative of the methylation status
(a) of the two CpG islands located within the promoter region of miR-23b or of (b) a 1536 bp region located 843 bp upstream and 597 bp
downstream of miR-23b. Methylation data are displayed as color-ﬁlled circle and the color spectrum indicates the range of methylation of
each CpG. Empty gray circles correspond to CpG sites that failed analysis. Data are reported as mean of three independents experiments.
(c) Quantitative reverse transcriptase–polymerase chain reaction analysis for miR-23b expression in KMS11 and MM1S cells treated with 1 μM
5-azacytidine (5-AZA) for 48 h. *Po0.01.
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miR-23b transfection was able to reduce the activity of NF-κB-
responsive elements in luciferase reporter assays (Figure 1e).
miR-23b is dowregulated MM and WM tumor cells
We examined miR-23b expression (Affymetrix, Santa Clara, CA,
USA) in CD138+ myeloma cells from 38 MM patients and 18
plasma cell leukemia patients and found it to be downregulated
compared with normal PCs (Figure 2a). The downregulation of
miR-23b expression was also observed in several MM cell lines
when compared with peripheral blood mononuclear cells and
bone marrow stromal cells from MM patients, and in additional
independent patient data set by quantitative PCR (Figure 2b).
Interestingly, we have observed lower expression of miR-23b in
WM, an indolent lymphoproliferative disease with high Sp1
activity8 (Figure 2c). Importantly we observed further down-
regulation of miR-23b expression in MM cells following interaction
with bone marrow milieu. Treatment with both IL-6 or supernatant
from MM-derived bone marrow stromal cell suppressed the
expression of miR-23b (Figure 2d) in a time- and dose-dependent
pattern (data not shown). Moreover, miR-23b is commonly
repressed in autoimmune conditions by IL-17 (ref. 24), a cytokine
shown to promote myeloma cell growth and inhibit its immune
function. We have indeed observed a further decrease in miR-23b
expression in MM cells after IL-17 treatment for 24 h. Our data
indicate that the human bone marrow microenvironment
modulates miR-23b levels in both MM and WM cells.
miR-23b is silenced by promoter hypermethylation in MM
Previous studies indicate that miR-23b is silenced in prostate
cancer25 and glioblastoma26 as a consequence of promoter
hypermethylation. We identiﬁed two CpG islands within the
miR-23b promoter (CpG promoter region 1 and CpG promoter
region 2, chr 9: 94725607-94726091 and 94726477-94726771,
respectively), which were then analyzed for their methylation
Figure 4. Functional role of miR23b replacement in MM and WM cells. (a) Cell growth of NCI-H929 myeloma cells stably expressing miR-23b
(V-miR-23b) or control (V-CNT) was evaluated by [3H]Thymidine uptake at the indicated time. Data are presented as cell growth increase
compared with Day 1. (b) Activation of Caspase-3, -8 and -9 was assessed by luminescence assay. (c) To test effects of miR-23b overexpression
on the malignant phenotype of MM and WM cells, we measured colony formation in semisolid, methylcellulose media. Representative phase
contrast images for H929 colonies formed in semisolid methylcellulose medium at day 21 for V-miR-23b and V-CNT cells are shown in the left
panel. In the right panel, graphs depict average colony numbers (mean± s.d.) for NCI-H929 and MWCL1 V-miR-23b and V-CNT cells in methyl
cellulose medium at day 21. (d) Transient transfection of miR-23b inhibited cancer cell survival as evaluated by cell titer glow assay, and
induced caspase-3 activation as evaluated by luminescence assay. Data are presented as % of control cells. (e) WB analysis conﬁrmed cleavage
of caspase-3 and -8 in cells transiently transfected with miR-23b mimics compared with control cells. (f) Growth curve assess tumor size after
subcutaneous injection of NCI-H929 myeloma cells transduced with miR-23b or scrambled control virus into the right posterior ﬂank region of
SCID mice. Data are shown as mean values± s.d.
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status in MM cells. As shown in Figure 3a, both KMS11 and MM1s
cells showed a high degree of methylation of CpGs within the CpG
promoter region 1. We also analyzed the methylation status of a
1536 bp CpG-rich region located 843 bp upstream and 597 bp
downstream of miR-23b (chromosome location: chr 9: 95084365-
95085901; Ensemble Genome Browser, Cambridge, UK), and
observed majority of the CpG sites methylated (Figure 3b). The
percentage of methylation of each CpG within the regions
analyzed is reported in Supplementary Figure S1. Importantly,
treatment of KMS11 and MM1s cells with the demethylating
compound 5-azacytidine resulted in upregulation of miR-23b
levels, as assessed by quantitative reverse transcriptase–PCR,
indicating that miR-23b promoter hypermethylation may con-
tribute to observed low miR-23b expression in MM (Figure 3c).
miR-23b overexpression suppresses cancer cell proliferation and
caspase-3 activation in vitro and in vivo. We further assessed the
functional signiﬁcance of miR-23b in MM and WM cells by gain of
function studies. A signiﬁcant decrease in cell proliferation along
with induction of caspase-3/7 activity was observed over time in
MM and WM cell lines stably expressing miR-23b compared with
control cells (Figures 4a and b). MiR-23b-transfected cells also had
low colony formation ability, as the number of foci in miR-23b-
expressing cells was decreased when compared with cnt-miR-
transfected cells (Figure 4c). These data were conﬁrmed using
transient transfection with miR-23b mimics (Figures 4d and e).
Finally, overexpression of miR-23b resulted in reduced tumor
growth in vivo in SCID mice over the course of 2 weeks when
compared with control cells (Figure 4f). These results indicate a
tumor growth suppressor role for miR-23b in MM and WM.
c-myc/Sp1 dependent regulation of miR-23b expression. To shed
light on the transcriptional regulation of miR-23b, we analyzed
miR-23b promoter regions and identiﬁed several putative binding
sites for oncogenic TFs such as c-myc, NF-kB and Sp1
(Supplementary Fig. 2). c-Myc, a known myeloma oncogenic TF,
has been already shown to transcriptionally repress miR-23a and
miR-23b in human prostate cancer cells;27 conversely, regulation
of miR-23b by Sp1 has not been previously reported. To evaluate
the effect of c-myc or Sp1 on miR-23b promoter transactivation,
we transfected U266 cells with a plasmid carrying the miR-23b
promoter cloned upstream of the luciferase reporter gene, along
with expression vectors encoding for c-myc or Sp1. Luciferase
assay demonstrated that c-myc or Sp1 overexpression reduced
miR-23b promoter activity, thus suggesting that both TFs
negatively regulate miR-23b expression (Figure 5a). To conﬁrm
transcriptional control of miR-23b by c-myc in MM, we evaluated
its expression level in cells either silenced or overexpressing
c-myc. Upon silencing of myc with speciﬁc siRNAs, we observed
increased miR-23b expression in a dose-dependent way
(Figure 5b). On the other hand, upregulation of c-myc in the
c-myc-negative U266 cell line decreased miR-23b expression
(Figure 5c). Importantly, we observed an inverse correlation
between c-myc and miR-23b levels in CD138+ cells from MM
patients (Figure 5d). Silencing of Sp1 by siRNAs in MM and WM
cells also resulted in upregulation of miR-23b expression levels
(Figure 5e).
Figure 5. Transcriptional repression of miR-23b by Myc. (a) U266 cells were transfected with a ﬁreﬂy luciferase construct containing the
miR-23b promoter, together with an Sp1 or c-myc expression constructs or the corresponding empty vectors; pCMV-RL was used for
normalizing ﬁreﬂy luciferase activity. Results are expressed as the ratio between ﬁreﬂy and renilla luciferase of three independent experiments
performed in triplicate. *Po0.01. (b) MM1S cells transfected using different concentrations of myc siRNA or scramble siRNA (Scr). Quantitative
PCR (qPCR) analyses conﬁrmed reduction in c-myc mRNA levels and increased miR-23b levels following transient transfection of MM1S cells
with c-myc siRNA compared with cells transfected with control scrambled siRNA. (c) Stable c-myc overexpression was achieved in U266 cell
line using Precision LentiORFs GFP-tagged. qPCR analyses conﬁrmed increased in c-myc mRNA levels and decreased miR-23b levels following
myc overexpression in U266. (d) Inverse correlation between mRNA levels of c-myc and miR-23b was evaluated in a cohort of 12 MM patients
by qPCR, Pearson correlation and linear regression analysis. R= regression coefﬁcient. (e) The effect of Sp1 knockdown on miR-23b in MM1S
and MWCL1 cells transfected with Sp1 or control siRNA was assessed by qPCR and presented as change relative to control cells.
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Extensive gene expression proﬁle analysis has provided interest-
ing insight into the disease biology, and its correlation with clinical
outcome is providing a new direction for risk stratiﬁcation as well
as novel targeted therapy. However, we have begun to realize the
signiﬁcant limitations of expression proﬁle data alone and there is
a growing understanding that additional genomic correlates need
to be considered for an integrated oncogenomic analysis.28
microRNAs (miRs), a class of small non-coding RNAs targeting
multiple mRNAs, are important transcriptome modiﬁers that alter
gene function, affect the tumor cell behavior and are aberrantly
expressed in myeloma.18,29 miRNA-23b (miR-23b), belonging to
the miR-23b–27b–24-1 cluster (9q22.32), is highly conserved in all
vertebrates. Among miRNAs, it has been described as a pleiotropic
modulator in different organs especially with regard to cancer
development and metastasis.30 MiR-23b, like other miRNAs, has
been found to be up- or downregulated in tumors compared with
normal tissues, thus supporting its dual role in carcinogenesis as
either a tumor suppressor or tumor promoter.23 miR-23b is
downregulated in human cancers such as prostate and colon
cancer, where it mediates the multiple steps of metastasis,
including tumor growth, invasion and angiogenesis in vivo.25,30–
33 In this study, we found miR-23b to be signiﬁcantly silenced/
downregulated in MM and WM as a consequence of several
mechanisms.
Promoter hypermethylation-dependent silencing of tumor
suppressor miRNAs has been frequently observed in hematologi-
cal malignancies.13,34 Here, we demonstrated for the ﬁrst time that
CpGs within miR-23b promoter regions are hypermethylated in
MM cells and miR-23b upregulation could be achieved by the
demethylating compound 5-azacytidine. Interestingly, treatment
with IL-6 or supernatant from bone marrow stromal cells resulted
in further decrease in miR-23b expression in MM and WM cells,
indicating that the human bone marrow microenvironment has a
prominent role in the modulation of miR-23b levels in myeloma
cells. Moreover, miR-23b is commonly repressed in autoimmune
conditions via IL-17 (ref. 24), a cytokine shown to promote
myeloma cell growth.35 We have indeed observed further
decrease in miR-23b expression in MM cells after IL-17 treatment
for 24 h. The suppression of miR-23b expression in tumors and
cancer cell lines suggests a tumor suppressor role in MM and WM.
However, neither the functional role nor the diagnostic or
prognostic implications of miR-23b in MM and WM have
been previously deﬁned. Both lentivirus- and synthetic
mimics-mediated enforced expression demonstrate that miR-23b
replacement causes a signiﬁcant decrease in cell proliferation and
survival over time in vitro and in vivo, along with induction of
caspase-3/7 activity.
Dysregulation of TF features prominently in the biology of
MM.6,36 Transcriptional regulators and miRs appear to cooperate
in the framework of a multigene transcriptional and post-
transcriptional feed-forward loop.37 At the molecular level, we
have identiﬁed Sp1, a TF endowed with oncogenic activity in MM
and WM, as a target of miR-23b. On the other hand, we report
here the transcriptional repression of miR-23b by c-myc, an
oncogenic TF known to regulate miRs38 and stimulate cell
proliferation.27,39 Thus MYC-dependent miR-23b repression in
myeloma cells may allow activation of oncogenic TFs Sp1 and
NF-κB, representing the ﬁrst feed-forward loop with critical growth
and survival role in myeloma.
Taken together, these data support a model in which the
humoral environment may confer a proliferative advantage partly
by reducing miR-23b expression in tumor cells, suggesting a
tumor suppressor role in MM and WM and highlighting the
potential of a miR-23b-targeted replacement therapy to treat
these hematologic malignancies.
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